Could One-Shot Vaccine And Mass Vax Site Improve COVID-19 Equity?

The first box of Johnson & Johnson’s COVID-19 vaccine departs from a facility in Shepherdsville, Ky., on Monday. The company is set to distribute its first 3.9 million doses across the U.S. this week.
The first box of Johnson & Johnson's COVID-19 vaccine departs from a facility in Shepherdsville, Ky., on Monday. The company is set to distribute its first 3.9 million doses across the U.S. this week.
The first box of Johnson & Johnson’s COVID-19 vaccine departs from a facility in Shepherdsville, Ky., on Monday. The company is set to distribute its first 3.9 million doses across the U.S. this week.
The first box of Johnson & Johnson's COVID-19 vaccine departs from a facility in Shepherdsville, Ky., on Monday. The company is set to distribute its first 3.9 million doses across the U.S. this week.

Could One-Shot Vaccine And Mass Vax Site Improve COVID-19 Equity?

The FDA approved Johnson & Johnson’s one-dose COVID-19 vaccine Saturday, setting off a scramble to distribute the shots and adding a dimension to the ongoing debate about how to ensure vaccination rolls out equitably in Chicago, Illinois and the nation.

Reset talks to a reporter and a local healthcare leader about whether the newly-greenlit J&J vaccine — as well as a new mass vaccination site at the United Center — could help vulnerable populations in the city get inoculated more quickly and more equitably.

GUESTS: Stephanie Goldberg, Crain’s Chicago Business health reporterDonna Thompson, CEO of ACCESS Community Health Network